Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 3 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Leukemia 6Neuroblastoma 4Lymphoma 4Leukemia, Myeloid, Acute 4Melanoma 3Sarcoma 2Rhabdomyosarcoma 2Radiation Injuries 2Malignant mesenchymal tumor 2Lymphoma, Follicular 2Leukemia, Myelomonocytic, Acute 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Monocytic, Acute 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2Head and Neck Neoplasms 2Congenital Abnormalities 2Breast Neoplasms 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Tongue Neoplasms 1Stomatitis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1

Interventions

Melphalan 3tebentafusp 1sargramostim 1fotemustine 1aflibercept 1Ranibizumab 1Nivolumab 1Neoadjuvant Therapy 1Melatonin 1MART-1 Antigen 1Ipilimumab 1Eye Enucleation 1Dacarbazine 1Colony-Stimulating Factors 1Chemotherapy, Cancer, Regional Perfusion 1Brachytherapy 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Uveal Melanoma × sargramostim × Clear all
NCT01989572 2020-07-07

Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery

National Cancer Institute (NCI)

Phase 3 Completed
815 enrolled 10 charts
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡